MassDevice is liveblogging the MassMEDIC 11th Annual Medtech Investors Conference. We’re talking to the officers and executives of some of the hottest under-the-radar medical device firms around, finding out how and why their technologies will separate them from the pack.
GlycoZym, Beverly, Mass.
GlycoZym is developing a next-generation diagnostic system and biomarkers for diseases including breast, ovarian, lung, prostate, colon and pancreatic cancers.
Officers
Thayer White, President & CEO
Directors
Thayer White, Greg Chase
Principal Investor
Greg Chase
Product
GlycoZym has initially targeted its discovery program to diseases for which underperforming biomarker monitoring tests currently exist, these including the most prevalent cancers such as breast cancer (current biomarker CA15-3) and ovarian cancer (current biomarker CA125); each have annual sales of over $400 million.
We have also had promising results with lung, prostate, colon and pancreatic cancers. Though GlycoZym will initially focus on diagnostics, PTM biomarkers have numerous therapeutic applications as well. GlycoZym is currently in discussion with potential partners to develop cancer therapeutic antibodies to our disease-specific PTM biomarkers.